SEC Form 4 · accession 0000880771-16-000215
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Friedhelm Blobel
Officer — President & CEO · Director
Period of report
Nov 21, 2016
Accepted (ET)
Nov 23, 2016 · 4:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 21, 2016 | M | 15,853 | $1.81 | A | 102,637 | D | |
| Common Stock | Nov 21, 2016 | S | 15,853 | $10.2283 | D | 86,784 | D | |
| Common Stock | Nov 21, 2016 | M | 40,000 | $1.81 | A | 126,784 | D | |
| Common Stock | Nov 21, 2016 | S | 40,000 | $10.2191 | D | 86,784 | D | |
| Common Stock | Nov 22, 2016 | M | 14,147 | $1.81 | A | 100,931 | D | |
| Common Stock | Nov 22, 2016 | S | 14,147 | $10.1976 | D | 86,784 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Options (right to buy)F2,F3 | $1.81 | Nov 21, 2016 | M | 15,853 | D | — | Mar 18, 2018 | Common Stock | 15,853 | 164,147 | D |
| Non-Qualified Stock Options (right to buy)F2,F3 | $1.81 | Nov 21, 2016 | M | 40,000 | D | — | Mar 18, 2018 | Common Stock | 40,000 | 124,147 | D |
| Non-Qualified Stock Options (right to buy)F2,F3 | $1.81 | Nov 22, 2016 | M | 14,147 | D | — | Mar 18, 2018 | Common Stock | 14,147 | 110,000 | D |
Explanation of responses
- F1The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2016.
- F2Granted under the Issuer's 2005 Equity Incentive Plan.
- F31/36th of such shares will vest on June 1, 2010 and 1/36th will vest monthly thereafter over a three-year period, provided the reporting person remains employed by the Company.